Voyager Therapeutics, Inc. (VYGR)
NASDAQ: VYGR · Real-Time Price · USD
3.000
-0.040 (-1.32%)
At close: Jul 29, 2026, 4:00 PM EDT
3.130
+0.130 (4.33%)
After-hours: Jul 29, 2026, 4:48 PM EDT
Voyager Therapeutics Employees
Voyager Therapeutics had 141 employees as of December 31, 2025. The number of employees decreased by 31 or -18.02% compared to the previous year.
Employees
141
Change (1Y)
-31
Growth (1Y)
-18.02%
Revenue / Employee
$258,823
Profits / Employee
-$827,213
Market Cap
181.26M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 141 | -31 | -18.02% | 141 | 0 |
| Dec 31, 2024 | 172 | 10 | 6.17% | 172 | 0 |
| Dec 31, 2023 | 162 | 37 | 29.60% | 162 | 0 |
| Dec 31, 2022 | 125 | 24 | 23.76% | 125 | 0 |
| Dec 31, 2021 | 101 | -78 | -43.58% | 101 | 0 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Invivyd | 122 |
| MediWound | 121 |
| Immunic | 95 |
| Alpha Cognition | 71 |
| Precision BioSciences | 66 |
| Pyxis Oncology | 56 |
VYGR News
- 16 days ago - Voyager Therapeutics presents six-month toxicology data for VY1706 - TheFly
- 16 days ago - Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer's Disease Expected H2 2026 - GlobeNewsWire
- 4 weeks ago - Voyager's Tau-Targeted Gene Therapy VY1706 for Alzheimer's Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026 - GlobeNewsWire
- 6 weeks ago - Voyager Therapeutics Transcript: 7th Annual HCW Neuro Perspectives Hybrid Conference - Transcripts
- 6 weeks ago - Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference - GlobeNewsWire
- 7 weeks ago - Voyager Therapeutics Transcript: AGM 2026 - Transcripts
- 2 months ago - Voyager Therapeutics announces FDA clearance for VY1706 IND application - TheFly
- 2 months ago - Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer's Disease - GlobeNewsWire